Acura Pharmaceuticals Receives Buy Rating from Roth Capital (ACUR)
Acura Pharmaceuticals (NASDAQ:ACUR)‘s stock had its “buy” rating reiterated by investment analysts at Roth Capital in a note issued to investors on Friday. They currently have a $1.50 target price on the stock, down from their previous target price of $2.50. Roth Capital’s price objective would indicate a potential upside of 73.41% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at TheStreet downgraded shares of Acura Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, June 3rd. Analysts at MLV & Co
downgraded shares of Acura Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 28th. They now have a $1.00 price target on the stock, down previously from $2.00.
Acura Pharmaceuticals (NASDAQ:ACUR) traded up 2.90% on Friday, hitting $0.8901. 83,161 shares of the company’s stock traded hands. Acura Pharmaceuticals has a 52 week low of $0.81 and a 52 week high of $2.23. The stock has a 50-day moving average of $1.02 and a 200-day moving average of $1.33. The company’s market cap is $43.5 million.
Acura Pharmaceuticals (NASDAQ:ACUR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.08) by $0.01. On average, analysts predict that Acura Pharmaceuticals will post $-0.16 earnings per share for the current fiscal year.
Acura Pharmaceuticals, Inc, is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.